ACE Technology Guidances

ACE Technology Guidances communicate recommendations from the MOH Drug Advisory Committee or the MOH Medical Technology Advisory Committee on the funding status and appropriate use of drugs, vaccines or medical technologies that have been evaluated by ACE. The guidances also include the Committee’s rationale for the funding recommendations, and key clinical and economic evidence which informed their deliberations. Plain English Summaries (PES) to explain ACE Technology Guidances are available for patients and the public.

Published on 01 Sep 2020
Last Updated on 04 Jan 2022
A- A+
Guidance Recommendations
The Ministry of Health’s Drug Advisory Committee has recommended:
  • Blinatumomab powder for infusion 35 mcg/vial for treating relapsed or refractory B-precursor acute lymphoblastic leukaemia (r/r B-ALL) for:
  • up to a maximum of two cycles for induction in a lifetime; and
  • up to three additional cycles for consolidation in a lifetime in patients who achieve a complete response after induction.

Patients with Philadelphia chromosome positive disease must have previously received a tyrosine kinase inhibitor before receiving blinatumomab.

Patients must not have received blinatumomab previously for the treatment of minimal residual disease (MRD)-positive B-ALL OR patients must have had a relapse-free period of at least six months following completion of treatment with blinatumomab for MRD.
Complete response is defined as a patient who:
  • has 5% or less bone marrow blasts; and
  • has no evidence of disease; and
  • has platelet count of more than 50,000 per microlitre; and
  • has absolute neutrophil count of more than 500 per microlitre.

Subsidy status

Blinatumomab powder for infusion 35mcg/vial is recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication.


Blinatumomab for treating relapsed or refractory B-ALL (4 Jan 2022) PES Blinatumomab for treating relapsed or refractory B-precursor acute lymphoblastic leukaemia (Updated 4 Jan 2022)